Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
02 Januar 2024 - 1:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced an abstract on pemvidutide in subjects
with Metabolic Dysfunction-Associated Steatotic Liver Disease1 will
be presented at the NASH-TAG Conference, which will be held in Park
City, UT on January 4-6, 2024. Pemvidutide is a novel,
investigational, peptide-based GLP-1/glucagon dual receptor agonist
in development for the treatment of obesity and MASH2. Details for
the presentation are as follows:
Title: |
Pemvidutide-Induced Liver Fat Reduction in Subjects with Metabolic
Dysfunction-Associated Steatotic Liver Disease Correlates with
Improvements in Non-Invasive Markers of Inflammation and Fibrosis:
Results of a 24-week Multicenter, Randomized, Double-Blind,
Placebo-Controlled Trial (abstract #51) |
Authors: |
Stephen A. Harrison, Shaheen Tomah, John J. Suschak, Jonathan
Kasper, M. Scot Roberts, M. Scott Harris, Sarah K. Browne |
Date: |
Saturday, January 6, 2024 |
A copy of the abstract will be accessible on the
Events section of the Altimmune website.
1previously termed Non-Alcoholic Fatty Liver
Disease2 previously termed NASH
About Altimmune Altimmune
is a clinical-stage biopharmaceutical company focused on developing
treatments for obesity and liver diseases. The Company’s lead
product candidate, pemvidutide, is a GLP-1/glucagon dual receptor
agonist that is being developed for the treatment of obesity and
MASH, formerly known as NASH. In addition, Altimmune is developing
HepTcell™, an immunotherapeutic designed to achieve a functional
cure for chronic hepatitis B. For more information, please visit
www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor Contact:Rich EisenstadtChief Financial
OfficerPhone: 240-654-1450reisenstadt@altimmune.com
Media Contact:Danielle CanteyEvoke CanalePhone:
619-826-4657danielle.cantey@evokegroup.com
Altimmune (NASDAQ:ALT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024